NCT06504147View on ClinicalTrials.gov

A Study of Radspherin® in Patients with Primary Advanced Epithelial Cancer, with Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

February 28, 2031

Conditions
Peritoneal CarcinomatosisOvarian Cancer
Interventions
DRUG

Radspherin

Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.

Trial Locations (6)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Unknown

RECRUITING

UZ Leuven, Leuven

RECRUITING

The Norwegian Radiumhospital, Oslo

RECRUITING

Clinica Universidad de Navarra, Madrid

RECRUITING

Clinica Universidad de Navarra, Pamplona

RECRUITING

Imperial College Healthcare NHS Trust, London

Sponsors

Lead Sponsor

Oncoinvent AS
All Listed Sponsors
lead

Oncoinvent AS

INDUSTRY

NCT06504147 - A Study of Radspherin® in Patients with Primary Advanced Epithelial Cancer, with Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | Biotech Hunter | Biotech Hunter